Batch of Telma AM earlier classified as NSQ now flagged as Spurious

Medical Dialogues team had reported that 93 drug formulations were declared as Not of Standard Quality (NSQ) in January 2025, based on testing conducted by various State Drug Control Authorities. Among these was a batch of TELMA AM (Batch No. 5240367), listed under Glenmark Pharmaceuticals Ltd., Solan (H.P.), which was flagged by the State Drugs Testing Laboratory, Kolkata for “not conforming to I.P. standards.”

Also Read: 93 Formulations Declared Not of Standard Quality as per Data Provided by States: CDSCO Drug Alert

However, the same batch has now also been classified as “purportedly spurious” in CDSCO’s revised alert, with Glenmark informing that it did not manufacture this batch.

The batch in question — Batch No. 5240367, with a manufacturing date of March 2024 and expiry of February 2027 — carries Glenmark’s name on the label. However, the company has officially clarified that it did not manufacture this particular batch.

“The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug,” the CDSCO stated in its revised alert.

The matter is now under active investigation. While the product is currently listed as “purportedly spurious,” the final classification will depend on the outcome of the ongoing inquiry.